Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
Information source: Canadian Retinal Trials Group
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Age-Related Macular Degeneration
Intervention: Triamcinolone Acetonide (Drug)
Phase: Phase 2/Phase 3
Status: Active, not recruiting
Sponsored by: Canadian Retinal Trials Group Official(s) and/or principal investigator(s):
David A Maberley, M.D., Study Director, Affiliation: University of British Columbia
Summary
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT
therapy in conjunction with intravitreal triamcinolone.
Clinical Details
Official title: Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Changes in visual acuity from baseline.
Secondary outcome: Change in lesion characteristics from baseline.
Detailed description:
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with
photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes
secondary to age-related macular degeneration.
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Individuals with predominantly classic, subfoveal CNV secondary to AMD.
- No previous PDT Treatment in study eye.
Exclusion Criteria:
- CNV from conditions, other than AMD.
- Other disease that could be responsible for decreased vision.
Locations and Contacts
Eye Care Centre, Vancouver, British Columbia, Canada
Additional Information
Starting date: January 2004
Ending date: March 2008
Last updated: July 26, 2007
|
